Harbor Investment Advisory LLC Increases Position in Novo Nordisk A/S (NYSE:NVO)

Harbor Investment Advisory LLC increased its stake in Novo Nordisk A/S (NYSE:NVO) by 9.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 1,800 shares of the company’s stock after acquiring an additional 153 shares during the quarter. Harbor Investment Advisory LLC’s holdings in Novo Nordisk A/S were worth $155,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Gabelli Funds LLC increased its holdings in Novo Nordisk A/S by 35.7% during the 2nd quarter. Gabelli Funds LLC now owns 46,963 shares of the company’s stock valued at $6,703,000 after acquiring an additional 12,363 shares in the last quarter. Xponance Inc. increased its holdings in Novo Nordisk A/S by 27.6% during the 2nd quarter. Xponance Inc. now owns 2,665 shares of the company’s stock valued at $380,000 after acquiring an additional 576 shares in the last quarter. Marshall Wace LLP increased its holdings in Novo Nordisk A/S by 34,472.1% during the 2nd quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock valued at $98,696,000 after acquiring an additional 689,441 shares in the last quarter. Insigneo Advisory Services LLC increased its holdings in Novo Nordisk A/S by 1.0% during the 2nd quarter. Insigneo Advisory Services LLC now owns 10,693 shares of the company’s stock valued at $1,526,000 after acquiring an additional 108 shares in the last quarter. Finally, Fred Alger Management LLC increased its holdings in Novo Nordisk A/S by 38.4% during the 2nd quarter. Fred Alger Management LLC now owns 54,493 shares of the company’s stock valued at $7,778,000 after acquiring an additional 15,129 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 0.5 %

Shares of NYSE:NVO opened at $80.59 on Thursday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The company has a fifty day simple moving average of $96.63 and a 200 day simple moving average of $116.04. The firm has a market cap of $361.65 billion, a PE ratio of 26.08, a price-to-earnings-growth ratio of 0.84 and a beta of 0.45. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on NVO shares. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. BMO Capital Markets lowered their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Finally, BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.